Health Care Equipment

WONDFO BIOTECH

WONDFO BIOTECH released FY2025 Annual Earnings on April 22 After-Market (BJT), actual revenue CNY 2.087 B (forecast CNY 2.301 B), actual EPS CNY -0.13 (forecast CNY 0.21)

WONDFO BIOTECH released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 581.74 M, actual EPS CNY 0.18

WONDFO BIOTECH released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 396.65 M, actual EPS CNY -0.3886

WONDFO BIOTECH to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

WONDFO BIOTECH to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 2.469 B, EPS CNY 0.545

WONDFO BIOTECH released FY2025 Q3 earnings on October 26 During-Market (BJT), actual revenue CNY 444.52 M, actual EPS CNY -0.1198

WONDFO BIOTECH released FY2025 9 Months Earnings on October 26 During-Market (BJT), actual revenue CNY 1.69 B, actual EPS CNY 0.2702

WONDFO BIOTECH to Release FY2025 Q3 Earnings on October 27 During-Market BJT

WONDFO BIOTECH released FY2025 Q2 earnings on August 19 Pre-Market (BJT), actual revenue CNY 445.38 M, actual EPS CNY 0.0001

WONDFO BIOTECH released FY2025 Semi-Annual Earnings on August 19 Pre-Market (BJT), actual revenue CNY 1.246 B, actual EPS CNY 0.3899

WONDFO BIOTECH FY2025 Semi-Annual Earnings Release on August 20, 2025 (BJT)

Wanfu Bio and Tencent Health Sign Strategic Cooperation Agreement in AI-Driven Healthcare

Wondfo Establishes Subsidiaries in Russia and the Philippines

Wanfu Biotechnology's Q1 2025 Revenue and Net Profit Both Decline

WONDFO BIOTECH released FY2025 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 800.28 M, actual EPS CNY 0.39

WONDFO BIOTECH to Release FY2025 Q1 Earnings on April 25 Pre-Market BJT

WONDFO BIOTECH released FY2024 Q4 earnings on April 9 After-Market (BJT), actual revenue CNY 883.45 M (forecast CNY 852 M), actual EPS CNY 0.2701 (forecast CNY 0.34)

WONDFO BIOTECH released FY2024 annual earnings on April 9 After-Market (BJT), actual revenue CNY 3.065 B (forecast CNY 3.265 B), actual EPS CNY 1.21 (forecast CNY 1.356)

WONDFO BIOTECH to Release FY2024 Earnings on April 10 After-Market BJT, Forecast Revenue 3.265 B CNY, EPS 1.356 CNY

Wondfo's US Subsidiary Obtains FDA 510(k) Approval

300482

Chinese companies are increasingly exporting in vitro diagnostic (IVD) products to Africa, leveraging their cost and quality advantages. Approximately 50-60% of bids for recent medical testing products received by the Foundation for Innovative New Diagnostics were from Chinese firms. The Senegalese market, previously dominated by European and US products, is now shifting towards more affordable Chinese options, particularly after improved China-Senegal relations. Wondfo Biotech's HIV test kits have become widely used in Senegal, breaking the monopoly of Western products. Chinese firms focus on meeting local needs, enhancing their appeal in developing markets.

Yicai

Edan

Africa Is New Growth Market for China-Made IVD Products

688317

002022

301080

300639

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

LIFERIVER

ACROBIOSYSTEMS

Hybribio Biotech

SSSW

Orient Biotech

DAJY

maccura

According to the Zhitong Finance APP, WONDFO BIOTECH released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders of the listed company was 134 million yuan, a year-on-year decrease of 69.32%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 82.6416 million yuan, a year-on-year decrease of 78.67%. The basic earnings per share were 0.28 yuan

Zhitong

WONDFO BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 134 million yuan, a decrease of 69.32%

According to the Zhitong Finance APP, WONDFO BIOTECH announced that the company plans to use its own funds to repurchase some of its shares through centralized bidding. The repurchased shares will be used entirely for implementing equity incentives or employee stock ownership plans. The total amount of funds for the repurchase will not be less than 30 million yuan (inclusive) and not exceed 60 million yuan (inclusive), with the repurchase price not exceeding 34.66 yuan per share (inclusive). The repurchase period is within 6 months from the date the board of directors approves the final repurchase plan

WONDFO BIOTECH plans to spend between 30 million and 60 million yuan to implement a share repurchase

According to the Zhitong Finance APP, WONDFO BIOTECH announced that the company recently received the medical device registration certificate issued by the Guangdong Provincial Drug Administration. The product names are: Fibrin (ogen) Degradation Product Determination Kit (Immunoturbidimetric Method), Fibrinogen Determination Kit (Coagulation Method), D-Dimer Determination Kit (Immunoturbidimetric Method), Anti Xa Determination Kit (Chromogenic Substrate Method)

WONDFO BIOTECH received multiple medical device registration certificates

According to WONDFO BIOTECH, recently, WONDFO BIOTECH signed a strategic agreement with the Ministry of Health of Côte d'Ivoire. According to the agreement, WONDFO BIOTECH will carry out in-depth cooperation with the healthcare system of Côte d'Ivoire in various fields such as production, education, research, and application

WONDFO BIOTECH signs strategic agreement with the Ministry of Health of Côte d'Ivoire

On the evening of August 20th, WONDFO BIOTECH announced that the company recently received the medical device registration certificate for the fully automated nucleic acid amplification analyzer issued by the National Medical Products Administration. This product is based on the principles of magnetic bead nucleic acid extraction and polymerase chain reaction technology, and is used in conjunction with matching detection reagents for qualitative detection of target nucleic acids derived from human samples in clinical settings, including pathogens and human gene projects

WONDFO BIOTECH: Fully automatic nucleic acid amplification analyzer has obtained the medical device registration certificate

According to the Zhitong Finance APP, WONDFO BIOTECH released its semi-annual report for 2025, showing an operating income of 1.246 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to shareholders of the listed company was 189 million yuan, a year-on-year decrease of 46.82%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 154 million yuan, a year-on-year decrease of 52.73%. The basic earnings per share were 0.39 yuan

WONDFO BIOTECH released its performance for the first half of the year, with a net profit attributable to the parent company of 189 million yuan, a decrease of 46.82%

WONDFO BIOTECH stated on the interactive platform that recently, the National Disease Control and Prevention Administration released the "Technical Guidelines for the Prevention and Control of Chikungunya Virus." WONDFO BIOTECH quickly responded by leveraging its colloidal gold and molecular diagnostics technology platforms to develop multiple chikungunya virus testing products, achieving a closed loop of "rapid screening - precise testing - monitoring," which can provide reliable monitoring solutions for disease control and inspection and quarantine at ports

WONDFO BIOTECH: Developed multiple products for detecting Chikungunya virus

WONDFO BIOTECH's wholly-owned subsidiary Shenzhen Tianshen Medical Devices Co., Ltd. recently obtained multiple medical device registration certificates. These registration certificates include various chemiluminescent immunoassay kits, such as tissue-type plasminogen activator-inhibitor 1 complex, fibrin (ogen) degradation products, and plasmin-α2 plasmin inhibitor complex, among others

WONDFO BIOTECH's subsidiary has obtained multiple medical device registration certificates

WONDFO BIOTECH(300482.SZ)